WO2002022784A3 - Expression, preparation, utilisations et sequence de la proteine hla-g soluble derivee par recombinaison - Google Patents
Expression, preparation, utilisations et sequence de la proteine hla-g soluble derivee par recombinaison Download PDFInfo
- Publication number
- WO2002022784A3 WO2002022784A3 PCT/US2001/029228 US0129228W WO0222784A3 WO 2002022784 A3 WO2002022784 A3 WO 2002022784A3 US 0129228 W US0129228 W US 0129228W WO 0222784 A3 WO0222784 A3 WO 0222784A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hla
- sequence
- domain
- soluble hla
- sequence homology
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001292773A AU2001292773A1 (en) | 2000-09-15 | 2001-09-17 | Expression, preparation, uses, and sequence of recombinantly-derived soluble hla-g |
US10/380,880 US20040044182A1 (en) | 2001-09-17 | 2001-09-17 | Expression, preparation,uses, and sequence of recombinantly-derived soluble hla-g |
CA002425186A CA2425186A1 (fr) | 2000-09-15 | 2001-09-17 | Expression, preparation, utilisations et sequence de la proteine hla-g soluble derivee par recombinaison |
EP01973167A EP1328290A2 (fr) | 2000-09-15 | 2001-09-17 | Expression, preparation, utilisations et sequence de la proteine hla-g soluble derivee par recombinaison |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23276100P | 2000-09-15 | 2000-09-15 | |
US60/232,761 | 2000-09-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002022784A2 WO2002022784A2 (fr) | 2002-03-21 |
WO2002022784A3 true WO2002022784A3 (fr) | 2002-06-06 |
Family
ID=22874459
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/029228 WO2002022784A2 (fr) | 2000-09-15 | 2001-09-17 | Expression, preparation, utilisations et sequence de la proteine hla-g soluble derivee par recombinaison |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1328290A2 (fr) |
AU (1) | AU2001292773A1 (fr) |
CA (1) | CA2425186A1 (fr) |
WO (1) | WO2002022784A2 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007011044A1 (fr) * | 2005-07-15 | 2007-01-25 | Kyushu University, National University Corporation | Composition pharmaceutique comprenant un dimere hla-g lie disulfide et procede de fabrication de ce dimere hla-g lie disulfide |
EP2184297A1 (fr) * | 2008-11-07 | 2010-05-12 | Hla-G Technologies | Polypeptides HLA-G et leurs utilisations pharmaceutiques |
EP2264067A1 (fr) * | 2009-06-18 | 2010-12-22 | Hla-G Technologies | Multimères de HLA-G alpha 1 et leurs utilisations pharmaceutiques |
US20120177671A1 (en) * | 2009-06-18 | 2012-07-12 | Hla-G Technologies | Hla-g alpha 1 multimers and pharmaceutical uses thereof |
EP2730588A1 (fr) | 2012-11-12 | 2014-05-14 | Intelectys | Anticorps et fragments de ceux-ci dirigés contre le domaine alpha-3 de protéine HLA-G, procédés et moyens pour leur préparation et leurs utilisations |
TW201829463A (zh) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | 抗hla-g抗體及其用途 |
KR20210098956A (ko) | 2018-09-27 | 2021-08-11 | 티조나 테라퓨틱스 | 항-hla-g 항체들, 항-hla-g 항체들을 포함하는 조성물들 및 항-hla-g 항체들을 이용하는 방법들 |
-
2001
- 2001-09-17 WO PCT/US2001/029228 patent/WO2002022784A2/fr not_active Application Discontinuation
- 2001-09-17 AU AU2001292773A patent/AU2001292773A1/en not_active Abandoned
- 2001-09-17 EP EP01973167A patent/EP1328290A2/fr not_active Ceased
- 2001-09-17 CA CA002425186A patent/CA2425186A1/fr not_active Abandoned
Non-Patent Citations (6)
Title |
---|
BAINBRIDGE ET AL.: "The short forms of HLA-G are unlikely to play a role in pregnancy because they are not expressed at the cell surface", JOURNAL OF REPRODUCTIVE IMMUNOLOGY, vol. 47, January 2000 (2000-01-01), pages 1 - 16, XP002908346 * |
BIASSONI R. ET AL.: "Natural killer cell-mediated recognition of human trophoblast", SEMINARS IN CANCER BIOLOGY, vol. 9, 1999, pages 13 - 18, XP002908344 * |
MALLET ET AL.: "Primary cultured human thymic epithelial cells express both membrane-bound and soluble HLA-G translated products", JOURNAL OF REPRODUCTIVE IMMUNOLOGY, vol. 43, 1999, pages 225 - 234, XP000989619 * |
ROUAS-FREISS N. ET AL.: "The immunotolerance role of HLA-G", SEMINARS IN CANCER BIOLOGY, vol. 9, 1999, pages 3 - 12, XP002908345 * |
SCHUST D. ET AL.: "HLA-G and HLA-C at the feto-maternal interface: lessons learned from pathogenic viruses", SEMINARS IN CANCER BIOLOGY, vol. 9, 1999, pages 37 - 46, XP002908343 * |
VAN DER VEN K. ET AL.: "HLA-G polymorphisms and molecule function-questions and more questions-a review", PLACENTA 2000, TROPHOBLAST RESEARCH, vol. 21, no. SUPPL. A, 2000, pages S86 - S92, XP002908347 * |
Also Published As
Publication number | Publication date |
---|---|
AU2001292773A1 (en) | 2002-03-26 |
CA2425186A1 (fr) | 2002-03-21 |
WO2002022784A2 (fr) | 2002-03-21 |
EP1328290A2 (fr) | 2003-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1308461A3 (fr) | Anticorps contre des bèta-amyloides ou leurs dérivés, et leurs utilisations | |
WO1999058675A3 (fr) | Genes humains et produits d'expression genique v | |
WO1999038972A8 (fr) | Genes humains et produits ii d'expression genique | |
WO1999033982A3 (fr) | Genes humains et produits d'expression genique i | |
AU2001276619A1 (en) | Immunisation against chlamydia pneumoniae | |
EP0909814A3 (fr) | Utilisation de protéine kinases pour le diagnostic et le traitement de la Maladie d'Alzheimer | |
CA2253636A1 (fr) | Polypeptide de la proteine-106 de la membrane externe de moraxella catarrhalis, sa sequence genetique et son utilisation | |
WO2003049762A3 (fr) | Immunisation contre chlamydia trachomatis | |
CA2102208A1 (fr) | Domaines de liaison dans les proteines notch et delta | |
RO117177B1 (ro) | Proteine recombinante, anti-obezitate, murine şi umane, secvenţă adn, care le codifică, procedeu de producere a proteinei şi conjugat cu acestea | |
WO2001025793A3 (fr) | Epitope diagnostique et therapeutique, et plante transgenique | |
WO2002014500A3 (fr) | Genes humains et produits d'expression genique | |
EP0175360A3 (fr) | Anticorps contre les peptides et leurs utilisation dans la détection des produits d'oncogènes | |
WO2001066753A3 (fr) | Nouveaux genes humains et leurs produits d'expression | |
IE893347L (en) | Antibody and dna sequence encoding it | |
WO2002022784A3 (fr) | Expression, preparation, utilisations et sequence de la proteine hla-g soluble derivee par recombinaison | |
GB9526178D0 (en) | Novel polynuceotides and polypeptides in pathogenic mycobacteria and their use as diagnostics,vaccines and targets for chemotherapy | |
EP0177814A3 (fr) | Anticorps contre les peptides et leurs utilisation dans la détection des produits d'oncogènes | |
NO975565L (no) | Benstimulerende faktor | |
WO2001042287A3 (fr) | Nouvelles proteines membranaires humaines et polynucleotides codant pour ces proteines | |
WO1999051188A3 (fr) | Polypeptide comprenant l'acide amine d'un produit tronque de la proteine a n-terminale fixant la choline, vaccin derive de ce polypeptide et ses utilisations | |
DE58909339D1 (de) | Humaner Papillomvirus Typ 57, seine DNA und die davon kodierten Proteine. | |
WO2000018916A3 (fr) | Genes humains et produits d'expression genique | |
CA2006587A1 (fr) | Proteines et peptides de membrane de haemophilus influenza de type b | |
BG105682A (en) | Bone stimulating factor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001973167 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2425186 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 2001973167 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10380880 Country of ref document: US |
|
WWR | Wipo information: refused in national office |
Ref document number: 2001973167 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001973167 Country of ref document: EP |